查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853643

生技药品契约製造市场按分子类型、製程步骤、生产规模、技术平台、治疗领域、最终用户和生产模式划分－2025-2032年全球预测

Biologics Contract Manufacturing Market by Molecule Type, Process Step, Production Scale, Technology Platform, Therapeutic Area, End User, Manufacturing Model - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，生技药品契约製造市场规模将达到 950 亿美元，复合年增长率为 17.28%。

关键市场统计数据
基准年 2024 265.3亿美元
预计年份：2025年 310.4亿美元
预测年份 2032 950亿美元
复合年增长率 (%) 17.28%

本文简要概述了科学突破和商业需求如何重塑生技药品契约製造策略和执行。

生技药品契约製造产业融合了科学创新、严格的监管要求和工业规模生产。过去十年，细胞和基因治疗、单株抗体、重组蛋白和疫苗研发的进步改变了人们对速度、灵活性和产品特定製程设计的期望。因此，契约製造生产商必须在确保不同客户专案品质一致并符合监管要求的同时，兼顾复杂的科学工作流程和产业限制。

更具体地说，企业日益面临着提供从上游研发到灌装、包装和分析测试的端到端服务的需求，同时还要应对从临床前测试到全面商业化生产的各种生产规模。这种不断变化的需求凸显了模组化设施设计和跨职能计划管理能力的重要性。此外，在选择一次性系统或传统不銹钢平台时，必须根据长期营运成本、污染风险和宣传活动弹性进行策略评估。

因此，那些将技术专长、敏捷的供应链管理和清晰的监管策略相结合的公司将获得决定性优势。本报告检验了这些动态，并为高管提供了必要的背景信息，以便他们将投资、伙伴关係和产能规划与定义生技药品成功生产的科学和商业性现实相协调。

技术进步、治疗方法多样化和供应链演变如何改变生技药品的生产实践和伙伴关係模式

生技药品契约製造格局正在经历一场变革，其驱动力包括技术成熟、治疗产品线的变化以及供应链中风险认知的转变。细胞和基因疗法等先进治疗方法正在引入高度个人化的产品形式，这需要客製化的製程开发、封闭式系统操作和严格的低温运输物流。同时，单株抗体和重组蛋白仍需要高通量、稳健的生产平台，并专注于产量优化和下游纯度。

向一次性技术的转变正在加速多宣传活动设施的灵活性，缩短週转时间，同时采购重点也转向经过检验的供应商，确保一次性组件的稳定供应。同时，注射用生技药品和组合药物最终产品完整性和包装的复杂性日益增加，使得填充和包装操作更加重要。监管体係也不断调整，对可比较性、病毒安全性和资料完整性的审查力度加大，提高了分析检测能力的要求。

因此，製造模式日益碎片化：一些赞助商倾向于使用专用设施以实现策略控制，而另一些则选择按服务收费或虚拟製造来节省资金并加快研发速度。这种累积效应迫使契约製造製造商透过提供基于平台的解决方案、投资于可适应性强的工艺流程以及加强与整个价值链的伙伴关係来保持竞争力并增强韧性。

评估美国关税调整对生技药品生产投入和策略采购决策的营运和供应链影响

预计2025年将推出的关税调整和贸易政策变化迫使企业重新评估筹资策略、供应商选择以及生产和采购的地理分布。进口一次性零件、特殊不銹钢配件和生物加工耗材的关税增加，可能会推高投入成本并挤压利润空间，除非製造商和赞助商采取补偿措施。

为此，许多公司正在加快供应商资格认证流程，拓展合格供应商名单，并探索近岸外包和回流生产方案，以减轻跨境关税的影响。这种转变正促使资金流入区域供应链和国内製造能力，尤其是高价值或关键型投入品。此外，采购团队也在重新谈判长期合同，并儘可能製定对冲策略，以稳定成本走势。

因此，关税压力也会影响新设施的位置决策，促使企业投资于可减少对高关税进口产品依赖的替代技术，并加强专案发起人和契约製造之间的合作，以共用风险。虽然关税会带来一些不利影响，但它们也能推动本地韧性的提升、供应商的发展以及策略性合约结构的构建，从而保障专案进度和产品品质。

详细的細項分析揭示了分子类型、製程步骤、生产规模、技术平台、治疗领域、最终用户和生产模式如何驱动产能需求。

一个完善的细分框架能够明确哪些方面需要提升能力以满足客户需求，以及哪些方面的投资能带来最大的营运回报。从细胞疗法、基因疗法、单株抗体、重组蛋白和疫苗等分子类型的角度进行细分，可以发现製程要求有显着差异。细胞和基因平台需要封闭式系统和专门的病毒载体处理工艺，而单株抗体则更专注于高效价上游工程和精细的下游纯化。

同样，将价值链按製程步骤（分析测试、下游、填充、配方和上游）分解，可以发现不同的技能组合、设备配置和监管要求，这些都必须在整个计划週期中进行协调。将生产规模从临床前研究分解为 I 期、II 期、III 期和商业化阶段，会带来节奏和生产力计画的挑战，因为不同平台技术和分子类别的放大路径差异显着。

技术平台的选择——一次性系统与不銹钢系统——也会影响设施布局、转换时间和验证策略。自体免疫、感染疾病、肿瘤和罕见疾病等治疗领域具有不同的风险接受度和计画进度，这会影响优先排序。生物技术公司、合约服务供应商、製药公司和研究机构等最终用户需要根据自身需求量身定制的合约模式和服务等级协议。最后，生产模式（专用设施、按服务收费、多产品设施、虚拟生产）决定了资本密集度、利润结构和商业性弹性。这些细分视角为能力蓝图提供讯息，并帮助高阶主管确定投资优先级，从而使营运设计与客户需求保持一致。

区域动态及其对全球市场产能分配、监管影响和跨境製造伙伴关係的策略意义

区域动态持续影响受託製造製造商和申办者的策略重点，他们需要评估产能分配和监管互动。在美洲，强大的生物技术生态系统和完善的法律规范支持着模组化生产能力的快速临床应用和私人投资，而该地区成熟的供应链则为研发阶段和商业化生产的稳健外包伙伴关係提供了保障。

相较之下，欧洲、中东和非洲呈现出异质性格局，高监管标准与各国对生物製造投资的不同奖励并存，而在中东和非洲的部分地区，区域政策倡议旨在透过有针对性的激励措施和官民合作关係来激活当地能力。

亚太地区已成为产能扩张的中心，这得益于其大规模製药生产经验、蓬勃发展的国内生物技术产业以及政府为保障生产自主权而采取的支持性倡议。儘管跨国合作在该地区依然可行，但决策者在位置和供应商合格方面，越来越重视地缘政治风险、贸易政策和区域物流韧性等因素。这些区域差异会影响企业进行研发活动的地点、合作伙伴的选择以及如何建立其全球生产网络，以平衡速度、成本和监管准入。

供应商如何透过技术专长、整合分析、策略合作伙伴关係和灵活的製造地来满足不同赞助商的需求，从而脱颖而出

领先的契约製造製造商和服务供应商正透过平台专业化、整合服务以及拓展技术深度和地理覆盖范围的投资来提升自身竞争力。一些公司专注于先进的治疗能力，例如病毒载体生产和封闭式细胞疗法工艺，而另一些公司则致力于扩大抗体和重组蛋白的生产规模，以支持大规模商业项目。在整个产业中，分析检测能力已成为一项重要的竞争优势，各公司纷纷增加高通量表征、效力测定和先进的生物分析技术，以缩短产品上市週期并支援复杂的可比性分析方案。

合作模式多种多样：与元件供应商建立策略联盟可确保一次性材料的持续供应，而与区域性企业成立合资企业则有助于快速进入市场并实现本地化供应。采用弹性製造系统并投资自动化技术的公司能够提高宣传活动效率和资料完整性，而那些优先考虑监管沟通和品质系统的公司则能降低核准风险并加速技术转移。最终，竞争优势源于将卓越的技术能力与服务编配相结合的能力，从而使客户能够顺利地将专案从早期研发阶段推进到商业化供应阶段，避免分散和不必要的延误。

为增强韧性、优化营运以及使生产能力蓝图与新兴的治疗方法和监管需求保持一致，提出切实可行的建议。

产业领导者应采取果断行动，增强韧性，提高成本效益，并从不断变化的治疗趋势中获取价值。首先，企业应优先考虑设施设计的模组化，并检验一次性製程和不銹钢製程的互通性，以保持宣传活动的灵活性并缩短换线时间。同时，投资强大的分析测试平台和可扩展的下游生产能力，可以简化可比性论证流程，并缩短复杂生技药品的上市时间。

其次，企业应实现关键消耗品和原料供应商组合的多元化，尽可能采取区域筹资策略，以加快供应商资格确认并降低关税和贸易风险。此外，营运负责人应制定正式的技术蓝图，包括增强自动化、数位化批次记录和流程分析技术，以提高可重复性和合应对力。第三，企业应评估混合製造模式，将策略专案的专用产能与高混合度和按服务收费的选项结合，以在确保客户机密性的同时优化产能利用率。

最后，加强与赞助商、学术中心和当地相关人员的伙伴关係，可以加快人才队伍建设，并促进与监管机构的互动。落实这些建议，将使我们能够应对治疗方法创新、政策变化和供应链波动，同时维持产品品质和专案连续性的高标准。

透过结合从业者访谈、监管分析、采购模式和技术文献的透明三角测量调查方法，获得可操作的见解。

本分析整合了来自行业访谈、技术白皮书、监管指南更新和已发布的策略文件的定性和定量资讯。此分析方法强调三角验证。来自高阶营运、品质和商业领导者的关键见解与技术文献和产品平臺揭露资讯进行交叉比对，检验营运影响和新兴趋势。此外，还检视了设备采购模式、专利活动和已报告的产能扩张情况，以推断平台采用和区域扩张的变化。

透过检验监管通知和测试结果，数据完整性得到提升，这突显了合规方面的重点关注领域，并加快了对病毒安全性、无菌保证和分析广度方面关键能力差距的识别。在适当情况下，使用了近期技术转移中的匿名案例研究，以说明实际的限制因素和成功的缓解策略。虽然本文讨论中未包含专有的定量预测，但调查方法透过记录资讯来源、访谈通讯协定以及用于评估技术和供应商的标准，确保了透明度。

总体而言，这种方法将实践者的经验与有据可查的证据相结合，为生技药品契约製造领域的管理人员在资本、采购和伙伴关係决策方面提供可操作且有理有据的见解。

总结关于产能投资、供应链韧性和伙伴关係模式调整以确保复杂生物製药可靠供应的观点

生技药品契约製造产业正处于一个关键时刻，科学创新与营运策略必须融合才能确保专案成功。对单株抗体和重组蛋白的持续需求，以及细胞和基因疗法的进步，都对製造商提出了技术深度和营运灵活性的双重要求。供应链压力和政策变化凸显了多元化采购和区域韧性的重要性，而一次性系统和不銹钢系统之间的技术选择则需要与专案风险状况和产能需求进行仔细匹配。

整合强大的分析能力、模组化设施设计和策略供应商关係的管理者，将更有能力将创新与可靠的供应连结起来。此外，采用灵活的商业模式，平衡专用产能和多样化产品，将使他们能够在不牺牲品质或速度的前提下满足多样化的客户需求。随着行业的不断发展，领导者必须使投资重点与治疗趋势和监管预期保持一致，以保持竞争力并确保患者能够获得复杂的生物製药。

这意味着，要取得进展，需要精心设计能力、积极主动地进行风险管理，以及建立合作伙伴关係，以提供开发和商业化现代生技药品所需的营运可靠性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 提高生技药品生产效率，越来越多采用连续生产平台
  • 营运成本降低和专业技能提升推动亚洲契约製造组织的扩张
  • 一次性生物反应器技术的整合降低了交叉污染的风险和停机时间。
  • 扩大外包伙伴关係，以加速基因和细胞疗法生产的规模化发展
  • 运用先进的分析和人工智慧技术优化生物製药製程产量比率并降低成本
  • 对品质合规性的监管审查日益严格，推动了对数位化批次记录系统和可追溯性的投资。
  • 为满足高细胞密度生产流程的需求，转向中空纤维和灌注式生物反应器
  • 开发用于快速扩大多功能生物製药生产线规模的模组化、灵活设施

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章生技药品契约製造市场（以分子类型划分）

  • 细胞疗法
  • 基因治疗
  • 单株抗体
  • 重组蛋白
  • 疫苗

第九章生技药品契约製造市场（依製程步骤划分）

  • 分析测试
  • 下游
  • 填充和精加工
  • 配方
  • 上游

第十章生技药品契约製造市场（依生产规模划分）

  • 商业的
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 临床前

第十一章生技药品契约製造市场：技术平台

  • 免洗系统
  • 不銹钢系统

第十二章生技药品契约製造市场（依治疗领域划分）

  • 自体免疫
  • 感染疾病
  • 肿瘤学
  • 罕见疾病

第十三章生技药品契约製造市场（依最终用户划分）

  • 生技公司
  • 签约服务供应商
  • 製药公司
  • 研究所

第十四章生技药品契约製造市场（依生产模式划分）

  • 专用设施
  • 服务费
  • 多产品工厂
  • 虚拟製造

第十五章生技药品契约製造市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章生技药品契约製造市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国生技药品契约製造市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Lonza Group Ltd.
    • Samsung Biologics Co., Ltd.
    • Catalent, Inc.
    • Wuxi Biologics（Cayman）Inc.
    • Thermo Fisher Scientific Inc.
    • Boehringer Ingelheim International GmbH
    • Fujifilm Diosynth Biotechnologies USA, Inc.
    • AGC Biologics Inc.
    • Recipharm AB
    • KBI Biopharma, Inc.
Product Code: MRR-8C74ADFBFD4E

The Biologics Contract Manufacturing Market is projected to grow by USD 95.00 billion at a CAGR of 17.28% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 26.53 billion
Estimated Year [2025] USD 31.04 billion
Forecast Year [2032] USD 95.00 billion
CAGR (%) 17.28%

A concise overview of how scientific breakthroughs and operational demands are reshaping biologics contract manufacturing strategy and execution

The biologics contract manufacturing sector operates at the confluence of scientific innovation, regulatory rigor, and industrial-scale production. Over the last decade, advances in cell and gene therapies, monoclonal antibodies, recombinant proteins, and vaccine development have shifted expectations for speed, flexibility, and product-specific process design. As a result, contract manufacturers must reconcile complex scientific workflows with industrial constraints while ensuring consistent quality and regulatory compliance across diverse customer programs.

More specifically, firms increasingly confront the need to provide integrated services that span upstream development through fill-finish and analytical testing, while accommodating varied production scales from preclinical runs to full commercial manufacture. This evolving requirement has amplified the importance of modular facility design and cross-functional project management capabilities. Moreover, technology choices between single-use systems and traditional stainless steel platforms now require strategic evaluation against long-term operational costs, contamination risk profiles, and campaign flexibility.

Consequently, companies that align technical expertise with responsive supply chain management and a clear regulatory strategy will gain a decisive advantage. This report examines those dynamics and provides the context necessary for executives to align investments, partnerships, and capacity planning with the scientific and commercial realities that define successful biologics manufacturing engagements.

How technological advances, therapeutic diversification, and supply chain evolution are jointly transforming biologics manufacturing practices and partnership models

The landscape of biologics contract manufacturing is undergoing transformative shifts driven by technological maturation, changing therapeutic pipelines, and evolving risk perceptions across supply chains. Advanced therapies such as cell and gene modalities have introduced highly personalized product formats that require bespoke process development, closed-system handling, and stringent cold-chain logistics. At the same time, monoclonal antibodies and recombinant proteins continue to demand high-throughput, robust manufacturing platforms that emphasize yield optimization and downstream purity.

Transitioning to single-use technologies has accelerated flexibility and reduced turnaround for multi-campaign facilities, yet it has also shifted procurement emphasis toward validated suppliers and disposable component supply security. In parallel, fill-finish operations have attracted renewed focus as final product integrity and packaging complexities increase with parenteral biologics and combination products. Regulatory regimes are adapting, with greater scrutiny on comparability, viral safety, and data integrity, thereby raising the bar for analytical testing capabilities.

As a result, manufacturing models are fragmenting: some sponsors favor dedicated facilities for strategic control, whereas others opt for fee-for-service or virtual manufacturing arrangements to preserve capital and speed development. The cumulative effect encourages contract manufacturers to offer platform-based solutions, invest in adaptable process trains, and strengthen partnerships across the value chain to remain competitive and resilient.

Assessing the operational and supply chain consequences of the United States tariff adjustments for biologics manufacturing inputs and strategic sourcing decisions

Anticipated tariff changes and trade policy adjustments announced for 2025 are prompting companies to reassess procurement strategies, supplier selection, and geographic distribution of manufacturing and sourcing. Tariff-driven increases on imported single-use components, specialized stainless steel fittings, and bioprocess consumables can elevate input costs and compress margins unless manufacturers and sponsors implement compensatory measures.

In response, many organizations are accelerating supplier qualification programs, diversifying approved vendor lists, and exploring nearshoring or reshoring alternatives to mitigate exposure to cross-border duties. These shifts are prompting capital deployment into regional supply chains and domestic manufacturing capacity, especially for high-value or mission-critical inputs. Additionally, procurement teams are renegotiating long-term agreements and developing hedging strategies where feasible to stabilize cost trajectories.

Consequently, tariff pressures also influence site selection decisions for new facilities, encourage investment in alternative technologies that reduce reliance on tariffed imports, and increase collaboration between sponsors and contract manufacturers to share risk. While tariffs present headwinds, they simultaneously create an impetus for localized resilience, supplier development, and strategic contract structures that protect program timelines and product quality.

Detailed segmentation analysis revealing how molecule types, process steps, production scales, technology platforms, therapeutic focuses, end users, and manufacturing models drive capability requirements

A robust segmentation framework clarifies where capabilities must align with customer needs and where investments will yield the greatest operational return. When segmentation is viewed through the lens of molecule types such as cell therapy, gene therapy, monoclonal antibody, recombinant protein, and vaccine, it becomes clear that process requirements diverge significantly: cell and gene platforms need closed systems and specialized viral vector processing, while monoclonal antibodies emphasize high-titer upstream processes and intensive downstream purification.

Similarly, dissecting the value chain by process steps-analytical testing, downstream, fill-finish, formulation, and upstream-reveals discrete skill sets, equipment footprints, and regulatory demands that must be coordinated across project timelines. Production scale segmentation from preclinical through Phase I, Phase II, Phase III, to commercial introduces cadence and capacity planning challenges, as scale-up pathways differ materially between platform technologies and molecule classes.

Technology platform choices between single-use systems and stainless steel systems also shape facility layout, changeover time, and validation strategies. Therapeutic areas such as autoimmune, infectious disease, oncology, and rare disease drive different risk tolerances and program velocities that affect prioritization. End users including biotechnology companies, contract service providers, pharmaceutical companies, and research institutes require tailored engagement models and service level agreements. Finally, manufacturing models-dedicated facility, fee-for-service, multiproduct facility, and virtual manufacturing-determine capital intensity, margin structure, and commercial flexibility. Together, these segmentation lenses inform capability roadmaps and help executives prioritize investments that align operational design with client needs.

Regional dynamics and strategic implications for capacity allocation, regulatory engagement, and cross-border manufacturing partnerships across global markets

Regional dynamics continue to shape strategic priorities for contract manufacturers and sponsors as they assess capacity allocation and regulatory engagement. In the Americas, strong biotech ecosystems and well-established regulatory frameworks favor rapid clinical translation and private investment into modular manufacturing capacity, while the region's mature supply chains support robust outsourcing partnerships for both discovery-stage work and commercial production.

In contrast, Europe, Middle East & Africa present a heterogeneous landscape where high regulatory standards coexist with varying national incentives for biomanufacturing investment. Several European markets emphasize advanced therapeutics and have strong academic-industry linkages that support translational pipelines, whereas regional policy initiatives in parts of the Middle East and Africa aim to bootstrap local capabilities through targeted incentives and public-private partnerships.

Asia-Pacific has emerged as a focal point for capacity expansion, driven by large-scale pharmaceutical manufacturing experience, growing domestic biotech sectors, and government-backed initiatives to secure manufacturing sovereignty. Across all regions, cross-border collaboration persists, but decision-makers are increasingly factoring geopolitical risk, trade policy, and regional logistics resilience into site selection and supplier qualification decisions. These regional nuances influence where companies place development activities, which partners they select, and how they sequence global production networks to balance speed, cost, and regulatory access.

How providers are differentiating through technical specialization, integrated analytics, strategic alliances, and flexible manufacturing footprints to meet diverse sponsor needs

Leading contract manufacturers and service providers are differentiating through platform specialization, integrated service offerings, and investments that expand both technical depth and geographic reach. Some firms concentrate on advanced therapy capabilities such as viral vector production and closed-system cell therapy processes, while others build scale in antibody and recombinant protein production to serve large-volume commercial programs. Across the sector, analytical testing proficiency has become a competitive differentiator, with companies adding high-throughput characterization, potency assays, and advanced bioanalytics to shorten release cycles and support complex comparability packages.

Partnership models also vary: strategic alliances with component suppliers ensure continuity of single-use materials, whereas joint ventures with regional players facilitate faster market entry and localized supply. Meanwhile, firms that adopt flexible manufacturing systems and invest in automation see improvements in campaign efficiency and data integrity, while those that prioritize regulatory engagement and quality systems reduce approval risks and accelerate tech transfers. Ultimately, competitive positioning derives from the ability to combine technical excellence with service orchestration, enabling clients to move programs from early development into commercial supply without fragmentation or unnecessary delay.

Actionable recommendations for strengthening resilience, optimizing operations, and aligning manufacturing capability roadmaps with emerging therapeutic and regulatory demands

Industry leaders should take decisive actions to strengthen resilience, improve cost-efficiency, and capture value from evolving therapeutic trends. First, organizations should prioritize modularity in facility design and validate the interoperability of single-use and stainless steel process trains to maintain campaign agility and reduce changeover time. Concurrently, investing in robust analytical testing platforms and scalable downstream capabilities will streamline comparability demonstrations and reduce release timelines for complex biologics.

Second, companies must diversify supplier portfolios for critical disposables and raw materials, accelerate supplier qualification, and pursue regional sourcing strategies where feasible to mitigate tariff and trade risks. In addition, operational leaders should formalize technology roadmaps that include increased automation, digital batch records, and process analytical technology to enhance reproducibility and regulatory readiness. Third, firms should evaluate hybrid manufacturing models that blend dedicated capacity for strategic programs with multiproduct and fee-for-service offerings to optimize utilization and preserve client confidentiality.

Finally, strengthening collaborative partnerships with sponsors, academic centers, and regional stakeholders will accelerate talent development and regulatory alignment. Implementing these recommendations will better position organizations to respond to therapeutic innovation, policy shifts, and supply chain perturbations while maintaining high standards of product quality and program continuity.

Transparent and triangulated research methodology combining practitioner interviews, regulatory analysis, procurement patterns, and technical literature to produce actionable insights

This analysis synthesizes qualitative and quantitative inputs drawn from industry interviews, technical white papers, regulatory guidance updates, and publicly reported strategic filings. The methodology emphasizes triangulation: primary insights from senior operations, quality, and commercial leaders were cross-referenced against technical literature and product pipeline disclosures to validate operational implications and emergent trends. Equipment procurement patterns, patent activity, and reported capacity expansions were examined to infer directional shifts in platform adoption and geographic deployment.

Data integrity was reinforced through validation of regulatory notifications and inspection outcomes, which helped surface areas of recurring compliance focus and accelerated the identification of critical capability gaps in viral safety, sterility assurance, and analytical breadth. Where appropriate, anonymized case studies from recent tech transfers were used to illustrate practical constraints and successful mitigation strategies. While proprietary quantitative projections were not included in this narrative, the methodology supports transparency by documenting sources, interview protocols, and criteria used for technology and supplier assessment.

Collectively, this approach balances practitioner experience with documentary evidence to produce actionable, defensible insights for executives making capital, sourcing, and partnership decisions in the biologics contract manufacturing space.

Concluding perspectives on aligning capability investment, supply chain resilience, and partnership models to reliably deliver complex biologic therapies

The biologics contract manufacturing sector stands at a pivotal moment where scientific innovation and operational strategy must converge to sustain program success. Advances in cell and gene therapies, alongside enduring demand for monoclonal antibodies and recombinant proteins, require manufacturers to be both technically deep and operationally nimble. Supply chain pressures and policy shifts highlight the importance of diversified sourcing and regional resilience, while technology choices around single-use versus stainless steel systems demand careful alignment with program risk profiles and throughput needs.

Executives who integrate robust analytical capabilities, modular facility design, and strategic supplier relationships will be better positioned to translate innovation into reliable supply. Moreover, adopting flexible commercial models that balance dedicated capacity with multiproduct offerings enables firms to serve diverse client needs without sacrificing quality or speed. As the industry evolves, leaders must synchronize investment priorities with therapeutic trends and regulatory expectations to maintain competitiveness and ensure patient access to complex biologic therapies.

In short, the path forward requires deliberate engineering of capabilities, proactive risk management, and collaborative partnerships that together deliver the operational reliability necessary for modern biologics development and commercialization.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of continuous manufacturing platforms to enhance biologic production efficiency
  • 5.2. Expansion of Asian contract manufacturing organizations driven by lower operational costs and expertise
  • 5.3. Integration of single-use bioreactor technologies to reduce cross-contamination risks and downtime
  • 5.4. Growing outsourcing partnerships to accelerate gene therapy and cell therapy manufacturing scale-up
  • 5.5. Implementation of advanced analytics and AI to optimize biologics process yields and reduce costs
  • 5.6. Increased regulatory scrutiny on quality compliance driving investment in digital batch record systems and traceability
  • 5.7. Shift towards hollow fiber and perfusion bioreactors to meet demand for high-cell density manufacturing processes
  • 5.8. Development of modular flexible facilities for rapid scale-up of multifunctional biologics production lines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Contract Manufacturing Market, by Molecule Type

  • 8.1. Cell Therapy
  • 8.2. Gene Therapy
  • 8.3. Monoclonal Antibody
  • 8.4. Recombinant Protein
  • 8.5. Vaccine

9. Biologics Contract Manufacturing Market, by Process Step

  • 9.1. Analytical Testing
  • 9.2. Downstream
  • 9.3. Fill Finish
  • 9.4. Formulation
  • 9.5. Upstream

10. Biologics Contract Manufacturing Market, by Production Scale

  • 10.1. Commercial
  • 10.2. Phase I
  • 10.3. Phase II
  • 10.4. Phase III
  • 10.5. Preclinical

11. Biologics Contract Manufacturing Market, by Technology Platform

  • 11.1. Single Use System
  • 11.2. Stainless Steel System

12. Biologics Contract Manufacturing Market, by Therapeutic Area

  • 12.1. Autoimmune
  • 12.2. Infectious Disease
  • 12.3. Oncology
  • 12.4. Rare Disease

13. Biologics Contract Manufacturing Market, by End User

  • 13.1. Biotechnology Company
  • 13.2. Contract Service Provider
  • 13.3. Pharmaceutical Company
  • 13.4. Research Institute

14. Biologics Contract Manufacturing Market, by Manufacturing Model

  • 14.1. Dedicated Facility
  • 14.2. Fee For Service
  • 14.3. Multiproduct Facility
  • 14.4. Virtual Manufacturing

15. Biologics Contract Manufacturing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Biologics Contract Manufacturing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Biologics Contract Manufacturing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Lonza Group Ltd.
    • 18.3.2. Samsung Biologics Co., Ltd.
    • 18.3.3. Catalent, Inc.
    • 18.3.4. Wuxi Biologics (Cayman) Inc.
    • 18.3.5. Thermo Fisher Scientific Inc.
    • 18.3.6. Boehringer Ingelheim International GmbH
    • 18.3.7. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
    • 18.3.8. AGC Biologics Inc.
    • 18.3.9. Recipharm AB
    • 18.3.10. KBI Biopharma, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. BIOLOGICS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOLOGICS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED FACILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED FACILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED FACILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED FACILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED FACILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED FACILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FEE FOR SERVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FEE FOR SERVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FEE FOR SERVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FEE FOR SERVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FEE FOR SERVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FEE FOR SERVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPRODUCT FACILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPRODUCT FACILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPRODUCT FACILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPRODUCT FACILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPRODUCT FACILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPRODUCT FACILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VIRTUAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VIRTUAL MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VIRTUAL MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VIRTUAL MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VIRTUAL MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VIRTUAL MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFOR